Basic characterization of 64Cu-ATSM as a radiotherapy agent
Creators
- 1. Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto 606-8151 (Japan)
- 2. Biomedical Imaging Research Center, University of Fukui, Matsuoka, Fukui 910-1193 (Japan)
- 3. JFE Fukui Branch, University of Fukui, Matsuoka, Fukui 910-1193 (Japan)
- 4. Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO 63110 (United States)
- 5. Research Center, Research and Development Division, Nihon Medi-Physics, Co. Ltd., Chiba 910-1193 (Japan)
Description
64Cu-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising radiotherapy agent for the treatment of hypoxic tumors. In an attempt to elucidate the radiobiological basis of 64Cu-ATSM radiotherapy, we have investigated the cellular response patterns in vitro cell line models. Cells were incubated with 64Cu-ATSM, and the dose-response curves were obtained by performing a clonogenic survival assay. Radiation-induced damage in DNA was evaluated using the alkali comet assay and apoptotic cells were detected using Annexin V-FITC and propidium iodide staining methods. Washout rate and subcellular distribution of 64Cu in cells were investigated to further assess the effectiveness of 64Cu-ATSM therapy on a molecular basis. A direct comparison of subcellular localization of Cu-ATSM was made with the flow tracer analog Cu-pyruvladehyde-bis(N4-methylthiosemicarbazone). In this study, 64Cu-ATSM was shown to reduce the clonogenic survival rate of tumor cells in a dose-dependent manner. Under hypoxic conditions, cells took up 64Cu-ATSM and radioactive 64Cu was highly accumulated in the cells. In the 64Cu-ATSM-treated cells, DNA damage by the radiation emitted from 64Cu was detected, and inhibition of cell proliferation and induction of apoptosis was observed at 24 and 36 h after the treatment. The typical features of postmitotic apoptosis induced by radiation were observed following 64Cu-ATSM treatment. The majority of the 64Cu taken up into the cells remained in the postmitochondrial supernatant (the cellular residue after removal of the nuclei and mitochondria), which indicates that the β- particle emitted from 64Cu may be as effective as the Auger electrons in 64Cu-ATSM therapy. These data allow us to postulate that 64Cu-ATSM will be able to attack the hypoxic tumor cells directly, as well as potentially affecting the peripheral nonhypoxic regions indirectly by the β- particle decay of 64Cu
Additional details
Identifiers
- DOI
- 10.1016/j.nucmedbio.2004.08.012;
- PII
- S0969-8051(04)00148-9;
Publishing Information
- Journal Title
- Nuclear Medicine and Biology
- Journal Volume
- 32
- Journal Issue
- 1
- Journal Page Range
- p. 21-28
- ISSN
- 0969-8051
- CODEN
- NMBIEO
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 36048845
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANOXIA; APOPTOSIS; CELL PROLIFERATION; COPPER 64; DNA DAMAGES; IN VITRO; MITOCHONDRIA; NEOPLASMS; PARTICLE DECAY; RADIATION DOSES; RADIOTHERAPY; SUBCELLULAR DISTRIBUTION; TUMOR CELLS
- Descriptors DEC
- ANIMAL CELLS; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; CELL CONSTITUENTS; COPPER ISOTOPES; DECAY; DISEASES; DISTRIBUTION; DOSES; ELECTRON CAPTURE RADIOISOTOPES; HOURS LIVING RADIOISOTOPES; INTERMEDIATE MASS NUCLEI; ISOTOPES; MEDICINE; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; RADIOISOTOPES; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.